In this study, we validated that hepatocyte growth factor (HGF) and IL-6 are predictive for bevacizumab, confirming results seen using pazopanib in renal cell carcinoma 17. The gene discussed is HGF; the disease is hereditary clear cell renal cell carcinoma.